Fig. 4

a LC3 flow cytometry staining to detect autophagy in the MG63, MG63 + Exo, MG63 + Exo/CDDP, and MG63/CDDP groups (left) and the HOS, HOS + Exo, HOS + Exo/CDDP, and HOS/CDDP groups (right). b The cell viability of the MG63, MG63 + Exo, MG63 + Exo/CDDP, MG63 + Exo/CDDP + miR-331-3p inhibitor, and MG63/CDDP groups after being treated with CDDP for 12, 24, and 48 h. The right part showed the results for HOS cells. c The mRNA expression of LC3 and p62 in the MG63, MG63 + Exo, MG63 + Exo/CDDP, MG63 + Exo/CDDP + miR-331-3p inhibitor, and MG63/CDDP groups after treatment using CDDP for 24 h (upper for MG63 and lower for HOS). d The protein levels of LC3 and p62 in the MG63, MG63 + Exo, MG63 + Exo/CDDP, MG63 + Exo/CDDP + miR-331-3p inhibitor, and MG63/CDDP groups after treatment using CDDP for 24 h. e The same for the HOS cells. **P < 0.01, ***P < 0.001, ****P < 0.0001 versus the MG63, HOS control group. ^#P < 0.05, ^##P < 0.01, ^###P < 0.001, ^####P < 0.0001 versus the MG63, HOS + exo/CDDP + miR-331 inhibitor group. CDDP, cisplatin; Exo, exosomes; LC3, microtubule-associated protein 1 light chain 3 alpha